Analysts Set Genelux Co. (NASDAQ:GNLX) PT at $26.75

Shares of Genelux Co. (NASDAQ:GNLX) have received a consensus recommendation of “Buy” from the six brokerages that are presently covering the company, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $26.75.

GNLX has been the topic of several recent analyst reports. Roth Capital upgraded shares of Genelux to a “strong-buy” rating in a research note on Tuesday, August 27th. Roth Mkm started coverage on shares of Genelux in a report on Tuesday, August 27th. They set a “buy” rating and a $10.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and set a $32.00 target price on shares of Genelux in a report on Thursday, August 15th. Finally, Benchmark reduced their target price on shares of Genelux from $30.00 to $25.00 and set a “speculative buy” rating for the company in a report on Friday, May 31st.

Insider Buying and Selling

In other Genelux news, major shareholder Aladar Szalay sold 51,630 shares of the company’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $2.11, for a total value of $108,939.30. Following the completion of the transaction, the insider now directly owns 1,048,191 shares in the company, valued at approximately $2,211,683.01. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders sold a total of 215,981 shares of company stock worth $449,177 in the last three months. 9.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Genelux

Several large investors have recently modified their holdings of GNLX. Woodward Diversified Capital LLC boosted its stake in Genelux by 2,326.2% during the fourth quarter. Woodward Diversified Capital LLC now owns 1,082,270 shares of the company’s stock worth $15,163,000 after acquiring an additional 1,037,663 shares in the last quarter. Armistice Capital LLC bought a new position in shares of Genelux in the second quarter valued at $1,755,000. Highbridge Capital Management LLC bought a new position in shares of Genelux in the second quarter valued at $1,231,000. Affinity Asset Advisors LLC purchased a new stake in Genelux in the 2nd quarter valued at about $195,000. Finally, Miracle Mile Advisors LLC bought a new position in shares of Genelux during the 2nd quarter worth approximately $58,000. 37.33% of the stock is currently owned by institutional investors and hedge funds.

Genelux Trading Up 9.6 %

Shares of GNLX stock opened at $2.17 on Thursday. The firm has a market capitalization of $74.54 million, a P/E ratio of -2.24 and a beta of -1.57. The firm’s fifty day moving average price is $2.11 and its two-hundred day moving average price is $3.77. Genelux has a 1 year low of $1.60 and a 1 year high of $30.44.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.